Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing's syndrome.
暂无分享,去创建一个
J. Moreno-Navarrete | J. Fernández-Real | W. Ricart | T. Puig | J. Farrerons | S. Webb | M. Barahona | E. Resmini | N. Sucunza
[1] N. Unwin,et al. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .
[2] G. Arnaldi,et al. Changes in adenosine 5'-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing's syndrome. , 2008, The Journal of clinical endocrinology and metabolism.
[3] W. Ricart,et al. Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women. , 2007, The Journal of clinical endocrinology and metabolism.
[4] C. Berne,et al. Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. , 2007, The Journal of clinical endocrinology and metabolism.
[5] L. Nieman,et al. Effects of Child‐ and Adolescent‐Onset Endogenous Cushing Syndrome on Bone Mass, Body Composition, and Growth: A 7‐Year Prospective Study Into Young Adulthood , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[6] Y. Kesäniemi,et al. Low plasma adiponectin concentration is an indicator of the metabolic syndrome. , 2006, European journal of endocrinology.
[7] P. Scherer,et al. Adipose tissue-derived factors: impact on health and disease. , 2006, Endocrine reviews.
[8] K. Ho,et al. Characterization of the metabolic phenotypes of Cushing's syndrome and growth hormone deficiency: a study of body composition and energy metabolism , 2006, Clinical endocrinology.
[9] E. Mannarino,et al. The endocrine function of adipose tissue: an update , 2006, Clinical endocrinology.
[10] R. Krauss,et al. Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.
[11] A. Colao,et al. The metabolic syndrome and cardiovascular risk in Cushing's syndrome. , 2005, Endocrinology and metabolism clinics of North America.
[12] B. Lukert,et al. Osteoporosis associated with excess glucocorticoids. , 2005, Endocrinology and metabolism clinics of North America.
[13] Jing Ma,et al. Inflammatory markers and the risk of coronary heart disease in men and women. , 2004, The New England journal of medicine.
[14] Jeremy W Tomlinson,et al. 11 (cid:1) -Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid Response , 2004 .
[15] J. Stepan,et al. Adipokine levels in Cushing's syndrome; elevated resistin levels in female patients with Cushing's syndrome , 2004, Clinical endocrinology.
[16] M. Boscaro,et al. Effect of glucocorticoids on adiponectin: a study in healthy subjects and in Cushing's syndrome. , 2004, European journal of endocrinology.
[17] S. Rubin,et al. Inflammatory Markers and Onset of Cardiovascular Events: Results From the Health ABC Study , 2003, Circulation.
[18] P. Stewart. Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action. , 2003, European journal of endocrinology.
[19] K. Godang,et al. Interleukin-1 receptor antagonist is associated with fat distribution in endogenous Cushing's syndrome: a longitudinal study. , 2003, The Journal of clinical endocrinology and metabolism.
[20] NoriyukiOuchi,et al. Association of Hypoadiponectinemia With Coronary Artery Disease in Men , 2003 .
[21] J. Mckenney,et al. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .
[22] H. Lochs,et al. Loss of body cell mass in Cushing's syndrome: effect of treatment. , 2002, The Journal of clinical endocrinology and metabolism.
[23] K. Godang,et al. Raised serum levels of interleukin-8 and interleukin-18 in relation to bone metabolism in endogenous Cushing's syndrome. , 2002, European journal of endocrinology.
[24] R. Marfella,et al. Reduction of Inflammatory Cytokine Concentrations and Improvement of Endothelial Functions in Obese Women After Weight Loss Over One Year , 2002, Circulation.
[25] S. Grundy,et al. National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .
[26] L. Nieman,et al. Glucocorticoid Excess During Adolescence Leads to a Major Persistent Deficit in Bone Mass and an Increase in Central Body Fat , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[27] P. Björntorp,et al. Occupational status, cortisol secretory pattern, and visceral obesity in middle-aged men. , 2000, Obesity research.
[28] G. Chrousos. The role of stress and the hypothalamic–pituitary–adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes , 2000, International Journal of Obesity.
[29] M. Rigla,et al. Recovery of hypopituitarism after neurosurgical treatment of pituitary adenomas. , 1999, The Journal of clinical endocrinology and metabolism.
[30] P. Marzullo,et al. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. , 1999, The Journal of clinical endocrinology and metabolism.
[31] W. Ricart,et al. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. , 1998, Diabetes.
[32] P. Stewart,et al. Does central obesity reflect “Cushing's disease of the omentum”? , 1997, The Lancet.
[33] J. Etxabe,et al. Morbidity and mortality in Cushing's disease: an epidemiological approach , 1994, Clinical endocrinology.